- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
April 4th, 2007
n health sector news, Australian bio-nanotech Psivida Ltd. surged 80 cents, or 39.2 percent, to $2.84 in the early session after signing an exclusive research and license agreement for its drug delivery technology with Pfizer Inc.
Under the agreement, which centers on ophthalmic, or eye-care products, Psivida will receive up to $155 million in development and sales-related milestone payments, and royalties on future products.
|Related News Press|
Aspen Aerogels to Present at the 28th Annual ROTH Conference March 14th, 2016
Arrowhead to Present at Upcoming March Conferences March 1st, 2016
Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers
Personal cooling units on the horizon April 29th, 2016
Exploring phosphorene, a promising new material April 29th, 2016
Researchers create a first frequency comb of time-bin entangled qubits: Discovery is a significant step toward multi-channel quantum communication and higher capacity quantum computers April 28th, 2016